The latest report by IMARC Group, titled “Meningococcal Vaccines Market Report by Vaccine Type (Conjugate, Polysaccharide, Subcapsular), Composition (Mono Vaccines, Combination Vaccines), Vaccine Serotype (MenACWY, MenB Manic, MenC, MenA, MenAC, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Institutional Sales, and Others), End User (Pediatric, Adult), and Region 2024-2032“, The global meningococcal vaccines market size reached US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2024-2032.
Meningococcal vaccines are essential in safeguarding individuals from infections caused by Neisseria meningitidis, commonly referred to as meningococcal bacteria. These vaccines are critical for public health, as they aid in the prevention of serious conditions such as meningitis and septicemia. Various types of meningococcal vaccines exist, including conjugate vaccines and serogroup B vaccines. Conjugate vaccines are notably effective, targeting specific strains of meningococcal bacteria (A, C, W, and Y) and are typically administered to adolescents and young adults. Conversely, serogroup B vaccines are specifically designed to address infections from meningococcal serogroup B and are particularly significant for individuals at an elevated risk. Contemporary meningococcal vaccines function by activating the immune system to generate antibodies against the bacteria, thus averting infection.
Meningococcal Vaccines Market Trends and Drivers:
The rising demand for meningococcal vaccines is largely attributed to an enhanced awareness of meningococcal diseases among both the general public and healthcare professionals. The serious nature of these illnesses, which can lead to conditions such as meningitis and septicemia, highlights the critical need for preventive measures and stimulates market growth. Furthermore, the introduction of more effective and safer vaccines, including conjugate vaccines that provide prolonged immunity and protection against various strains, has played a significant role in this expansion. Investments by pharmaceutical companies in research and development (RD) have resulted in the launch of new vaccines and heightened competition, further driving market advancement. Moreover, enhancements in healthcare infrastructure and improved access to medical services in developing nations have facilitated the availability and uptake of meningococcal vaccines, thereby accelerating market progress.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/meningococcal-vaccines-market/requestsample
The report has segmented the market into the following categories:
Breakup by Vaccine Type:
- Conjugate
- Polysaccharide
- Subcapsular
Breakup by Composition:
- Mono Vaccines
- Combination Vaccines
Breakup by Vaccine Serotype:
- MenACWY
- MenB Manic
- MenC
- MenA
- MenAC
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Breakup by End User:
- Pediatric
- Adult
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc.
- Incepta Pharmaceuticals Limited
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Serum Institute of India Ltd.
- Walvax Biotechnology Co. Ltd.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
